ATE278017T1 - Humaner k+ ionenkanal und therapeutische verwendungen davon - Google Patents

Humaner k+ ionenkanal und therapeutische verwendungen davon

Info

Publication number
ATE278017T1
ATE278017T1 AT99920731T AT99920731T ATE278017T1 AT E278017 T1 ATE278017 T1 AT E278017T1 AT 99920731 T AT99920731 T AT 99920731T AT 99920731 T AT99920731 T AT 99920731T AT E278017 T1 ATE278017 T1 AT E278017T1
Authority
AT
Austria
Prior art keywords
nucleic acid
methods
ion channel
present
relates
Prior art date
Application number
AT99920731T
Other languages
German (de)
English (en)
Inventor
Luis Angel Pardo-Fernandez
Walter Stuehmer
Synnoeve Beckh
Andrea Brueggemann
Camino Fernandez-Miranda D Del
School Medical
Perez Araceli Sanchez
Ruediger Weseloh
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Application granted granted Critical
Publication of ATE278017T1 publication Critical patent/ATE278017T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT99920731T 1998-04-21 1999-04-21 Humaner k+ ionenkanal und therapeutische verwendungen davon ATE278017T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98107268 1998-04-21
PCT/EP1999/002695 WO1999054463A2 (en) 1998-04-21 1999-04-21 Human k+ ion channel and therapeutic applications thereof

Publications (1)

Publication Number Publication Date
ATE278017T1 true ATE278017T1 (de) 2004-10-15

Family

ID=8231794

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99920731T ATE278017T1 (de) 1998-04-21 1999-04-21 Humaner k+ ionenkanal und therapeutische verwendungen davon

Country Status (10)

Country Link
US (7) US6638736B1 (enExample)
EP (1) EP1073738B1 (enExample)
JP (2) JP2002512029A (enExample)
AT (1) ATE278017T1 (enExample)
CA (1) CA2323571A1 (enExample)
DE (1) DE69920681T2 (enExample)
DK (1) DK1073738T3 (enExample)
ES (1) ES2230852T3 (enExample)
PT (1) PT1073738E (enExample)
WO (1) WO1999054463A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2230852T3 (es) * 1998-04-21 2005-05-01 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Canales ionicos de k+humanos y aplicaciones terapeuticas de los mismos.
DE10025620A1 (de) * 2000-05-24 2001-12-06 Forschungsgesellschaft Genion Verfahren zur Herstellung von Chimären zwischen bakteriellen und eukaryotischen Kaliumkanälen auf festen Trägern und deren Verwendung zur Identifizierung von Kaliumkanalagonisten und -antagonisten
DE10224534A1 (de) 2002-05-31 2003-12-11 Juergen Dolderer Verfahren zum Diagnostizieren des colorektaien Karzinoms in einer Gewebeprobe und Mittel zur Behandlung
MX2007003865A (es) * 2004-10-01 2009-06-17 Ct Investig Y Estudios Del Ipn Métodos para el diagnóstico temprano de infecciones virales y enfermedades inflamatorias o de la predisposición de un individuo a desórdenes proliferativos o hiperplasia.
ATE497508T1 (de) 2004-10-01 2011-02-15 Max Planck Gesellschaft Gegen das säugetier-eag1-ionenkanalprotein gerichtete antikörper
AU2013201604B2 (en) * 2007-04-13 2014-08-14 Southern Research Institute Anti-angiogenic agents and methods of use
ES2334084B1 (es) * 2007-12-21 2011-01-24 Inst Cientifico Tecnol Navarra Marcadores geneticos para el pronostico de la esclerosis multiple.
US8892184B2 (en) 2010-10-18 2014-11-18 Siemens Medical Solutions Usa, Inc. Systems and methods for reducing interference in a dual modality imaging system
TWI570415B (zh) * 2015-10-02 2017-02-11 A spring probe having an outer sleeve and a probe device having the spring probe
EP3195727A1 (en) 2016-01-22 2017-07-26 Forschungsinstitut Fur Biologischen Landbau (FiBL) Duddingtonia flagrans strain and feed additive formulation for biological pest control

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
GB9303210D0 (en) 1993-02-17 1993-03-31 Univ Manitoba Cancer treatment
WO1992011034A1 (en) 1990-12-18 1992-07-09 The Wellcome Foundation Limited Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
WO1998000168A1 (en) * 1996-07-02 1998-01-08 Novartis Consumer Health S.A. Topical composition comprising a combination of antihistaminic compounds with terpenoid compounds
US6610827B1 (en) * 1997-10-29 2003-08-26 Elan Pharmaceuticals, Inc. Potassium channel subunit polypeptide and polynucleotide compositions and uses therefor
ES2230852T3 (es) * 1998-04-21 2005-05-01 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Canales ionicos de k+humanos y aplicaciones terapeuticas de los mismos.

Also Published As

Publication number Publication date
EP1073738B1 (en) 2004-09-29
US20030087377A1 (en) 2003-05-08
DK1073738T3 (da) 2005-01-24
US20030092120A1 (en) 2003-05-15
US20080020406A1 (en) 2008-01-24
US7364730B2 (en) 2008-04-29
EP1073738A2 (en) 2001-02-07
US6638736B1 (en) 2003-10-28
US7364845B2 (en) 2008-04-29
US7129207B2 (en) 2006-10-31
US20100021467A1 (en) 2010-01-28
JP2009235091A (ja) 2009-10-15
ES2230852T3 (es) 2005-05-01
JP2002512029A (ja) 2002-04-23
CA2323571A1 (en) 1999-10-28
US7314914B2 (en) 2008-01-01
WO1999054463A2 (en) 1999-10-28
WO1999054463A3 (en) 2000-04-20
DE69920681T2 (de) 2005-09-08
US20030077735A1 (en) 2003-04-24
DE69920681D1 (de) 2004-11-04
US20030087378A1 (en) 2003-05-08
PT1073738E (pt) 2005-01-31

Similar Documents

Publication Publication Date Title
Zhu et al. Janus kinase inhibition ameliorates ischemic stroke injury and neuroinflammation through reducing NLRP3 inflammasome activation via JAK2/STAT3 pathway inhibition
Nakatsuji et al. A commensal strain of Staphylococcus epidermidis protects against skin neoplasia
Yin et al. Transglutaminase 2 inhibition reverses mesenchymal transdifferentiation of glioma stem cells by regulating C/EBPβ signaling
Zhang et al. Propofol induces proliferation and invasion of gallbladder cancer cells through activation of Nrf2
Namyen et al. Protective effects of melatonin on methamphetamine-induced blood–brain barrier dysfunction in rat model
Sheehan et al. Improving the radiosensitivity of radioresistant and hypoxic glioblastoma
BR0009505A (pt) Compostos e processos para terapia e diagnóstico de câncer de pulmão
Shou et al. Type I interferons exert anti-tumor effect via reversing immunosuppression mediated by mesenchymal stromal cells
Hou et al. The inhibitory effect of IFN-γ on protease HTRA1 expression in rheumatoid arthritis
ATE389724T1 (de) Menschliche dnase i hyperaktive varianten
TR200103560T2 (tr) Göğüs kanserinin teşhis ve tedavisi için bileşimler ve bunların kullanımı
Carvalho et al. Chemosensitization by erythropoietin through inhibition of the NF-κB rescue pathway
Ahmed et al. Combinatory Effects of Bone Marrow‐Derived Mesenchymal Stem Cells and Indomethacin on Adjuvant‐Induced Arthritis in Wistar Rats: Roles of IL‐1β, IL‐4, Nrf‐2, and Oxidative Stress
RU2768186C2 (ru) Комбинированные лекарственные средства, содержащие модуляторы pkm2 и hmgb1
Li et al. USP21 regulates Hippo signaling to promote radioresistance by deubiquitinating FOXM1 in cervical cancer
ATE278017T1 (de) Humaner k+ ionenkanal und therapeutische verwendungen davon
Pozzi et al. MCP-1/CCR2 axis inhibition sensitizes the brain microenvironment against melanoma brain metastasis progression
Fritsch et al. TNF induced cleavage of HSP90 by cathepsin D potentiates apoptotic cell death
Welk et al. Proteasome activator PA200 regulates myofibroblast differentiation
BRPI0407544A (pt) derivados de pirazol tetracìclicos como inibidores da cinase, processo para a sua preparação e composições farmacêuticas que os compreendem
Gelati et al. Methylprednisolone acts on peripheral blood mononuclear cells and endothelium in inhibiting migration phenomena in patients with multiple sclerosis
Wang et al. Chlorotoxin targets ERα/VASP signaling pathway to combat breast cancer
Chen et al. Progesterone boosts abiraterone-driven target and NK cell therapies against glioblastoma
WO2001029068A3 (en) A eag gene encoding for a potassium channel
JPS61155324A (ja) 癌治療薬剤

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1073738

Country of ref document: EP

REN Ceased due to non-payment of the annual fee